A4
Differential expression of genes in disseminated and metastatic tumour cells from patients with metastatic breast cancer
Eitan Amir, Thomas Cawthorn, Reuben Broom, Orit Freedman, David Barth, Dongju Wang, Susan Done, Mark Clemons
Princess Margaret Hospital, Toronto, Canada
Background
The molecular mechanisms underlying the development of bone metastases (BM)
in breast cancer remain unclear. Disseminated tumour cells (DTCs) in the bone
marrow of breast cancer patients have been identified, but their potential to
initiate metastases is not known. We prospectively evaluated the genetic
differences between DTCs in the bone marrow and metastatic tumour cells (MTCs)
obtained from computed tomography (CT) guided biopsies of radiologically
confirmed bone metastases.
Method
Thirteen breast cancer patients with BM underwent a CT-guided BM biopsy and
a bone marrow aspiration (for DTCs). Tumour cells were enriched by
immunomagnetic separation and RNA was extracted from each sample. Gene
expression profiling was conducted using Illumina Human Ref-8 bead arrays
comprising 24,500 gene probes. Microarray data was analyzed using BeadStudio
software to identify differentially expressed genes. Ingenuity Pathway Analysis
software was used to identify genes integral to specific pathways postulated to
be involved in cancer metastasis.
Results
A signature of 133 candidate genes differentially expressed between the two
sample types was identified. Paired analysis of samples obtained from the
same patient identified a subset of 161 genes, of which 52 overlapped with the
initial unmatched signature. Several genes relevant to breast cancer metastasis
to bone (i.e. osteopontin, CTGF, parathyroid hormone receptor, EGFR) were
significantly overexpressed in MTCs compared to DTCs.
Conclusion
Our results suggest that there are specific subsets of genes required for
breast cancer cells to form overt bone metastases. A number of genes identified
participate in the vicious cycle model of osteolytic bone metastases
formation. This work provides the foundation for further investigation and may
aid in the identification of novel therapeutic targets for metastasis
inhibition.